RxDoctor Payments Data

Elizabeth Bird

Family · Fredericksburg, VANPI 1376018739

Payments from drug & device makers

$4,448in general payments, 2019–2025

Across 168 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$652
  • E.r. Squibb & Sons, L.L.C.$509
  • AstraZeneca$490
  • Novartis$352
  • Amgen$349
  • Abbott$285
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,448 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$55,840
Medicare patients
323
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$232,116
EntrestoSacubitril/Valsartan43$56,157
JardianceEmpagliflozin37$42,740
XareltoRivaroxaban25$28,075
FarxigaDapagliflozin Propanediol13$19,316
Repatha SureclickEvolocumab14$16,391
VascepaIcosapent Ethyl22$15,878
Carvedilol ErCarvedilol Phosphate11$4,206
Rosuvastatin Calcium244$4,159
Dofetilide17$3,468
Ezetimibe120$3,215
Ranolazine ErRanolazine23$2,599
Bisoprolol Fumarate38$2,284
Olmesartan Medoxomil27$1,743
Metoprolol Succinate130$1,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123$232,116182 claims
NovartisEntresto$352$56,15743 claims
Boehringer IngelheimJardiance$16$42,74037 claims
Johnson & JohnsonXarelto$13$28,07525 claims
AstraZenecaFarxiga$490$19,31613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →